Delayed sustained release pharmaceutical compositions

1. A pharmaceutical composition consisting of:

a plurality of immediate release beads, each immediate release bead consisting of an amphetamine core, wherein the amphetamine core consists of at least one amphetamine salt and an optional binder layered onto or incorporated into an inert core;

a plurality of delayed release beads, each delayed release bead consisting of an immediate release bead and a delayed release coating layered thereover, wherein the delayed release coating consists of a copolymer of methacrylic acid and ethyl acrylate and an optional excipient, and is present at a coating level of about 25% to about 30% by weight of the bead; and

a plurality of delayed sustained release beads, each delayed sustained release bead consisting of an immediate release bead, a sustained release coating layered over the immediate release bead, and a delayed release coating layered over the sustained release coating, wherein the sustained release coating consists of ethyl cellulose and is present at a coating level from about 5% to about 9% by weight of the bead, and the delayed release coating consists a copolymer of methacrylic acid, methyl methacrylate, and methyl acrylate and an optional excipient, and is present at a coating level from about 20% to about 25% by weight of the bead;

wherein the pharmaceutical composition has a d-amphetamine T max from 7.9 hours to 8.8 hours after administration of a 30 mg dose of the pharmaceutical composition to a fasting human subject.

2. The pharmaceutical composition of claim 1 , wherein the at least one amphetamine salt is dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, amphetamine sulfate, or mixtures thereof, and the at least one amphetamine salt is present in the pharmaceutical composition in an amount from 12.5 mg to 75 mg.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has a d-amphetamine C max from about 41 ng/ml to about 44 ng/mL, and a d-amphetamine AUC inf from about 884 ng·h/mL to about 934 ng·h/mL after administration of a 30 mg dose of the pharmaceutical composition to a fasting human subject.

4. The pharmaceutical composition of claim 1 , wherein the pluralities of immediate release beads, delayed release beads, and delayed sustained release beads are incorporated into a capsule.

5. The pharmaceutical composition of claim 1 , wherein the pluralities of immediate release beads, delayed release beads, and delayed sustained release beads are incorporated into a tablet.

6. The pharmaceutical composition of claim 1 , wherein each of the pluralities of immediate release beads, delayed release beads, and delayed sustained release beads comprises 33.3% by weight of the at least one amphetamine salt.

7. A method for treating for treating attention deficit hyperactivity disorder (ADHD), the method comprises administering to a patient in need thereof the pharmaceutical composition of claim 1 .